Amended 8-K Reveals Financials for Massive Scorpius Asset Acquisition, Adding $16.3M Convertible Debt

summarizeSummary

Tivic Health Systems filed an amended 8-K providing financial details for its December 2025 acquisition of Scorpius Holdings' assets for $16.25 million cash and $16.3 million in new convertible debt, a massive transaction relative to Tivic's market cap.

check_boxKey Events

• Financials Disclosed for Major Acquisition

  This 8-K/A provides the financial statements and pro forma information for the acquisition of Scorpius Holdings' assets, which was initially announced in December 2025. This completes the disclosure for a highly significant transaction.

• Substantial Acquisition Cost

  Tivic's subsidiary, Velocity Bioworks, Inc., paid $16.25 million in cash for the assets and issued a new senior secured convertible note to 3i, LP for $16.3 million, representing a total transaction value of approximately $32.5 million.

• Strategic Shift to In-House Manufacturing

  The acquisition brings manufacturing and related services for Tivic's late-stage oncology asset, Entolimod, in-house and aims to expand its CDMO business, aligning with a previously announced strategic pivot to oncology.

• Acquisition of Distressed Assets

  Scorpius Holdings, Inc. was in default on secured convertible notes, leading to a foreclosure sale of its assets. Tivic acquired these assets from a financially distressed entity, which could present both opportunities and integration challenges.

auto_awesomeAnalysis

This amended 8-K provides the crucial financial statements and pro forma information for Tivic Health Systems' acquisition of substantially all assets of Scorpius Holdings, Inc., which occurred on December 10, 2025. The acquisition, valued at approximately $16.25 million in cash and an additional $16.3 million in new convertible debt issued by Tivic, represents an enormous financial commitment for a company with a market capitalization of less than $2 million. The strategic rationale is to bring manufacturing for Tivic's late-stage oncology asset, Entolimod, in-house and expand its contract development and manufacturing organization (CDMO) services. However, the acquisition of a distressed entity (Scorpius was in default and undergoing foreclosure) and the significant increase in Tivic's debt burden, especially given its recent history of highly dilutive financings and current trading near 52-week lows, introduces substantial financial risk. Investors should carefully assess the long-term strategic benefits against the immediate and considerable financial leverage.